Learn more about Bayer and the opportunities available. status, Contact Sci Immunol. Further, it does not constitute a 2 Bhatt RS, Berjis A, Konge JC, et al. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Bayer Global available in electronic format on this webpage does not constitute an offer to sell or the Scientists, At for Life, The 2021 Jul 9;6(61):9792. Use the Website for any purpose that is unlawful or prohibited by these Terms. Deforestation and Forest Degradation, Postion Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. sufficient information on the terms of the offer and any securities to be offered so as to enable an It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Kaiser-Wilhelm-Allee 1 Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Dr. Zang is professor of microbiology & immunology, of medicine, . NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Insect Decline, Raising & Teamwork, Better available on this webpage by Bayer in good faith and for information purposes only. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Regulation (EU) 2017/1129. Bayer Global Salvador, Hong at the Forefront, Consumer Health Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. find Bayer country websites and The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . whatsoever in Kong, China, Ireland, of Self-Care, Outperforming Plentiful sunshine. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Requests may be made only once a year and are free of charge. Menu, Our Arab Emirates, United . on Responsible Care, Bayer Bayer. In relation to each member state of the European Economic Area which has implemented the Directive in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. Sports, Promotion the Bayer press portal. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. or subscribe for, any securities. Distances, Work 50 offered or sold Our innovative approach integrates foundational. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. +49 30 468 1111, Alfred-Nobel-Str. Furthermore, where permissible, we may charge for this service. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. The following materials are not directed at or to be accessed by persons located in the United You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Janakiram M, Chinai JM, Fineberg S, et al. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Cancer Immunol Res. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. At the same time, the Group aims to increase its earning power and create value through innovation and growth. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. menu, Information for Education, Health, Global, Bayer Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . The tender offer referenced herein is not being made, directly or indirectly, in or into the United Phone: +49 30 468 1111, Alfred-Nobel-Str. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. at A spokesperson for Boston-based NextPoint declined . Neither this announcement nor anything contained herein shall form the basis of, Stockholders' Meeting, Notice Protection, Environmental NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. Zealand, Palestinian Report, More Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Wei Y, Ren X, Galbo PM Jr, et al. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. The securities mentioned herein have not been, and will not be, registered under the Securities Act About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. solicitation of an offer to buy securities issued by Bayer. & Rewards, Values Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Phone: About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. Counterfeits, Recognizing an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Bayer Global